Treating hepatitis may improve patient outcomes in myeloma
A dysregulated immune response against viruses that cause hepatitis may lead to some cases of multiple myeloma (MM) — and in these cases, treating…
A dysregulated immune response against viruses that cause hepatitis may lead to some cases of multiple myeloma (MM) — and in these cases, treating…
Adding Darzalex Faspro (daratumumab and hyaluronidase) — a subcutaneous or under-the-skin formulation of Darzalex (daratumumab) — to a standard combination therapy regimen led to…
The U.S. Food and Drug Administration (FDA) is delaying its review of an application that seeks to allow the cell therapy Abecma (idecabtagene vicleucel) to…
A committee of the European Medicines Agency (EMA) has recommended that Elrexfio (elranatamab) — a therapy already in use in the U.S. — be…
While diabetes is more frequent among Black people than white people, it’s associated with poorer survival outcomes in white people with multiple myeloma, a…
People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the…
Nanjing Leads Biolabs is planning to launch a first-in-human clinical trial to test LBL-034, an antibody-based therapy designed to trigger the immune system to…
Researchers at Tel Aviv University in Israel have developed a new nanoparticle system that can deliver RNA-based therapies designed to kill myeloma cells in…
The U.S. Food and Drug Administration (FDA) has placed a hold on clinical testing of CART-ddBCMA, a cell therapy that Arcellx and Kite…
Carvykti (ciltacabtagene autoleucel) significantly reduces the risk of disease progression or death in adults with multiple myeloma who received one to three prior lines…